| 168.22 -4.13 (-2.4%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 241.43 | 1-year : | 281.99 |
| Resists | First : | 206.71 | Second : | 241.43 |
| Pivot price | 182.74 |
|||
| Supports | First : | 110.05 | Second : | 50.31 |
| MAs | MA(5) : | 171.79 |
MA(20) : | 162.8  |
| MA(100) : | 71.3 |
MA(250) : | 62.37 |
|
| MACD | MACD : | 25.7 |
Signal : | 31 |
| %K %D | K(14,3) : | 26.6 |
D(3) : | 43.5 |
| RSI | RSI(14): 60.4 |
|||
| 52-week | High : | 206.71 | Low : | 26.7 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRAX ] has closed above bottom band by 18.8%. Bollinger Bands are 15.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 172.49 - 173.44 | 173.44 - 174.22 |
| Low: | 157.19 - 158.48 | 158.48 - 159.53 |
| Close: | 166.24 - 168.24 | 168.24 - 169.86 |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Thu, 06 Nov 2025
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Thu, 06 Nov 2025
Praxis Precision Medicines (NASDAQ: PRAX) grants 6,876 RSUs under 2024 Inducement Plan - Stock Titan
Thu, 06 Nov 2025
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Wed, 05 Nov 2025
Praxis Precision Medicines Reports Q3 2025 Financial Results - TipRanks
Wed, 05 Nov 2025
Praxis Precision Medicine’s Soaring Success: What Will Happen Next? - timothysykes.com
Wed, 05 Nov 2025
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1.595e+007 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 2,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.7135e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 497.5 % |
| Return on Equity (ttm) | -38 % |
| Qtrly Rev. Growth | 7.76e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -23.1 |
| EBITDA (p.s.) | -8.11439e+007 |
| Qtrly Earnings Growth | -12.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -191 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -7.29 |
| Price to Cash Flow | 23.11 |
| Dividend | 0 |
| Forward Dividend | 2.61e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|